12:00 AM
Mar 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FGF-2: Phase I data; Phase II

CHIR said that rFGF-2 was safe and well tolerated across a number of doses in a Phase I study. A total of 52 patients with severe CAD received a single 20 minute...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >